![MC2-25-C1](https://www.adcreviews.com/wp-content/uploads/2022/09/MC2-25-C1-300x200.jpeg)
MC2-25-C1 new drug for uremic pruritus starts phase II clinical trial
On September 14, MC2 Therapeutics announced that it had completed the first patient dosing of the Phase II MC2-25-C1 trial. The trial was designed to
On September 14, MC2 Therapeutics announced that it had completed the first patient dosing of the Phase II MC2-25-C1 trial. The trial was designed to